Alfuzosin GITS (Xatral XL)
PreclinicalSmall molecule
Alfuzosin GITS (Xatral XL) is one of 12 small molecule programs targeting Urinary retention. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Urinary Retention
#DrugCompanyPhaseTrials
1Flomax
SanofiApproved
Robinul
Jazz PharmaceuticalsApproved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Avodart
Akero TherapeuticsApproved
Esmeron
FFresenius Kabi USA, LLC
Approved
Ivadantin
PProcter and Gamble
Approved
Tamsulosin OCAS
AstellasPhase 3
No Intrathecal Morphine
UUniversity of Toronto
Phase 3
Minipress
PfizerPreclinical
Decadron
AAspen Global Incorporated
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alfuzosin GITS (Xatral XL). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHospital Authority, Hong Kong